Eli Lilly’s blockbuster obesity drug, Mounjaro, became India’s top-selling drug by value in October. Sales hit $11.38 million, said research firm Pharmarack, on Friday.

Mounjaro is an anti-obesity drug that helps control blood sugar and slow digestion that was launched in March. Its rival, Novo Nordisk's Wegovy, was launched in June and has since then generated a revenue of over $37 million till end of October. Advertisement

Mounjaro's consumption in India, on the other hand, was 10 times more than Wegovy by volume in October, the firm said.

This once-weekly injectable, targeting both GLP-1 and GIP receptors, is priced between Rs 14,000 and Rs 17,500 per month.

India’s anti-obesity drug market has undergone substantial growth, and had reached Rs 628 crore as of the twelve months endin

See Full Page